These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27714060)

  • 41. Identification of several circulating microRNAs from a genome-wide circulating microRNA expression profile as potential biomarkers for impaired glucose metabolism in polycystic ovarian syndrome.
    Jiang L; Huang J; Chen Y; Yang Y; Li R; Li Y; Chen X; Yang D
    Endocrine; 2016 Jul; 53(1):280-90. PubMed ID: 26860517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Study of circulating hepcidin in association with iron excess, metabolic syndrome, and BMP-6 expression in granulosa cells in women with polycystic ovary syndrome.
    Kim JW; Kang KM; Yoon TK; Shim SH; Lee WS
    Fertil Steril; 2014 Aug; 102(2):548-554.e2. PubMed ID: 24875397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of epistasis in the etiology of Polycystic Ovary Syndrome among Indian women: SNP-SNP and SNP-environment interactions.
    Dasgupta S; Reddy BM
    Ann Hum Genet; 2013 Jul; 77(4):288-98. PubMed ID: 23550965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
    Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of novel serum metabolic biomarkers in patients with polycystic ovarian syndrome and premature ovarian failure.
    Chen J; Zhou Q; Zhang Y; Tan W; Gao H; Zhou L; Xiao S; Gao J; Li J; Zhu Z
    Bioengineered; 2021 Dec; 12(1):8778-8792. PubMed ID: 34696698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of Potential Biomarkers for Urine Metabolomics of Polycystic Ovary Syndrome Based on Gas Chromatography-Mass Spectrometry.
    Zou Y; Zhu FF; Fang CY; Xiong XY; Li HY
    Chin Med J (Engl); 2018 Apr; 131(8):945-949. PubMed ID: 29664055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can serum apolipoprotein C-I demonstrate metabolic abnormality early in women with polycystic ovary syndrome?
    Huang S; Qiao J; Li R; Wang L; Li M
    Fertil Steril; 2010 Jun; 94(1):205-10. PubMed ID: 19368908
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
    Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
    Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine.
    Selen Alpergin ES; Bolandnazar Z; Sabatini M; Rogowski M; Chiellini G; Zucchi R; Assadi-Porter FM
    Physiol Rep; 2017 Jan; 5(1):. PubMed ID: 28082426
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis.
    Jung J; Kim SH; Lee HS; Choi GS; Jung YS; Ryu DH; Park HS; Hwang GS
    Clin Exp Allergy; 2013 Apr; 43(4):425-33. PubMed ID: 23517038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
    Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
    Reprod Health; 2015 Jan; 12():7. PubMed ID: 25595199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in whole metabolites after exenatide treatment in overweight/obese polycystic ovary syndrome patients.
    Tang L; Yuan L; Yang G; Wang F; Fu M; Chen M; Liu D
    Clin Endocrinol (Oxf); 2019 Oct; 91(4):508-516. PubMed ID: 31271659
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Searching for the primary metabolic alterations of polycystic ovary syndrome by application of the untargeted metabolomics approach.
    Rajska A; Buszewska-Forajta M; Macioszek S; Wawrzyniak R; Wityk P; Berg A; Kowalewska A; Rachoń D; Markuszewski MJ
    J Pharm Biomed Anal; 2023 Oct; 235():115602. PubMed ID: 37536113
    [TBL] [Abstract][Full Text] [Related]  

  • 54. (1)H NMR based metabolomic profiling revealed doxorubicin-induced systematic alterations in a rat model.
    Niu QY; Li ZY; Du GH; Qin XM
    J Pharm Biomed Anal; 2016 Jan; 118():338-348. PubMed ID: 26595282
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
    Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
    Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How to Screen and Prevent Metabolic Syndrome in Patients of PCOS Early: Implications From Metabolomics.
    Zhao X; Feng X; Zhao X; Jiang Y; Li X; Niu J; Meng X; Wu J; Xu G; Hou L; Wang Y
    Front Endocrinol (Lausanne); 2021; 12():659268. PubMed ID: 34149613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome.
    Galazis N; Iacovou C; Haoula Z; Atiomo W
    Eur J Obstet Gynecol Reprod Biol; 2012 Feb; 160(2):121-30. PubMed ID: 22136882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome].
    Parahuleva N; Pehlivanov B; Orbecova M; Uchikova E; Ivancheva H
    Akush Ginekol (Sofiia); 2014; 53(5):22-7. PubMed ID: 25558667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.
    Rajkhowa M; Neary RH; Kumpatla P; Game FL; Jones PW; Obhrai MS; Clayton RN
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3389-94. PubMed ID: 9329374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined transcriptome and metabolome analyses of metformin effects reveal novel links between metabolic networks in steroidogenic systems.
    Udhane SS; Legeza B; Marti N; Hertig D; Diserens G; Nuoffer JM; Vermathen P; Flück CE
    Sci Rep; 2017 Aug; 7(1):8652. PubMed ID: 28819133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.